Journal: Reproductive Biology and Endocrinology : RB&E

Article Title: linc00958/miR-185-5p/RSF-1 modulates cisplatin resistance and angiogenesis through AKT1/GSK3β/VEGFA pathway in cervical cancer

doi: 10.1186/s12958-022-00995-2

Figure Lengend Snippet: Antibodies used in western blot and IHC experiments

Article Snippet: The primary antibody against VEGFA (bs-4572R, Bioss, Beijing, China) was diluted with 1% donkey serum (1:200) and then added in each well.

Techniques: Western Blot

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the rabbit study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Placement of VEGF-A mRNA injections in relation to the microdialysis probe in the pig study. For further details, see methods.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in eluates from 100 kDa microdialysis probes intradermally inserted in the rabbit hind leg. Microdialysis was started at t=0 h and four id injections of VEGF-A mRNA injections (50 μ g each) were given at t=1 h. Dotted line indicates Lower Limit of Quantification (LLOQ, 33.4 pg/mL). Two probes were inserted in each rabbit. Values shown are mean ± SEM (n=4).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques:

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Concentrations of human VEGF-A in microdialysis eluates from 100 kDa microdialysis probes intradermally inserted on the pig (n=3) abdomen. Values presented as individual values in eluate from each probe. Six intradermal VEGF-A mRNA injections (50 μ L each, total 24, 120, or 600 μ g VEGF-A mRNA) were given at t=0 h. At t=1.5 h after the injections, microdialysis was started. Eluates were collected during the time intervals from 1.5 h to 3.5 h, from 3.5 h to 5.5 h, and from 5.5 h to 7.5 h, respectively. Dotted vertical line indicates Lower Limit of Quantification (33.4 pg/mL); eluate samples below LLOQ are depicted as 0.5 ∗ LLOQ=16.7 pg/mL. Six probes were inserted in each pig, two probes per dose except the 120 μ g dose, where only four probes were used to assess human VEGF-A production following injection of 24 or 600 μ g VEGF-A mRNA. The remaining two probes were used to study effects following injection of citrate/saline vehicle.

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection, Saline

Journal: BioMed Research International

Article Title: Rapid Production of Human VEGF-A following Intradermal Injection of Modified VEGF-A mRNA Demonstrated by Cutaneous Microdialysis in the Rabbit and Pig In Vivo

doi: 10.1155/2019/3915851

Figure Lengend Snippet: Amounts (pg/mg) of human VEGF-A in skin biopsies excised approximately 8 hours after intradermal injection of VEGF-A mRNA in 3 pigs. Each dose was administered as 6 (24 and 600 μ g dose) or 4 (120 μ g dose) separate injections at two different sites in each pig. Hatched data point in the 24 μ g dose, depicted at 0.1 pg/mg, indicating amount below Lower Limit of Quantification (0.28 pg/mg).

Article Snippet: An Alexa-labelled detection antibody against human VEGF-A (R&D systems) was then flowed through the column and the florescence intensity was used for quantification of the ligand.

Techniques: Injection

Journal: Reproductive biology

Article Title: Angiogenic factors measured in aspirated placental tissue between the 10 + 6 and 18 + 3 weeks of gestation.

doi: 10.1016/j.repbio.2021.100572

Figure Lengend Snippet: Fig. 1. VEGF-A and eNOS concentration in chorionic villous sample according to the gestational age.

Article Snippet: VEGF-A was quantified by enzyme immunoassay (Human VEGF Quantikine ELISA Kit, R&D Systems, Wiesbaden-Nordenstadt, Germany).

Techniques: Concentration Assay

Journal: Stem cells translational medicine

Article Title: External Application of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Hyaluronic Acid Gel Repairs Foot Wounds of Types I and II Diabetic Rats Through Paracrine Action Mode.

doi: 10.1093/stcltm/szad050

Figure Lengend Snippet: Figure 2. Histopathological features of diabetic foot wound closure in type I diabetic (T1DM) rats on day 21. (A) Representative micrographs of HE staining, scale bar = 500 μm (40×) and 50 μm (400×). (B) Representative micrographs of Masson’s trichrome stained sections, scale bar = 500 μm (40×) and 50 μm (400×). (C) Histogram of collagen deposition from Masson’s trichrome. (D) Representative micrographs of VEGFA antibody immunohistochemistry and blood vessels labeled by yellow allows, scale bar = 500 μm (40×) and 50 μm (400×). (E) Quantification of immunohistochemical staining intensity (VEGFA antibody). (F) Quantification of average number of blood vessels. Data were mean ± SD. *P < .05 and **P < .01 vs the control group, #P < .05 and ##P < .01 vs the model group, $P < .05 and $$P < .01 vs the HA group.

Article Snippet: The antibodies against PCNA (NB500-106) and VEGFA (NB100-664) were purchased from Novus Biologicals, Inc., the antibodies against β-actin (A3854), p-p38 (Thr180/Tyr182, 4511), total p38 (87869), total JNK (9252S), p-JNK (Thr183/Tyr185, 9255S), p-ERK1/2 (p-p44/42, Thr202/Tyr204, 4370), total ERK1/2 (p44/42, 4695), p-Akt (Ser473, 4060T), and total Akt (4691T) were purchased from Cell Signaling Technology, Inc., and horseradish peroxidase–conjugated antibody was purchased from Zhongshan Jinqiao Biotechnology Co., Ltd.

Techniques: Staining, Immunohistochemistry, Labeling, Immunohistochemical staining, Control

Journal: Stem cells translational medicine

Article Title: External Application of Human Umbilical Cord-Derived Mesenchymal Stem Cells in Hyaluronic Acid Gel Repairs Foot Wounds of Types I and II Diabetic Rats Through Paracrine Action Mode.

doi: 10.1093/stcltm/szad050

Figure Lengend Snippet: Figure 3. Histopathological features of diabetic foot wounds closure in type II diabetic (T2DM) rats on day 21. (A) Representative micrographs of H&E staining, scale bar = 500 μm (40×) and 50 μm (400×). (B) Representative micrographs of Masson’s trichrome stained sections, scale bar = 500 μm (40×) and 50 μm (400×). (C) Histogram of collagen deposition from Masson’s trichrome. (D) Representative micrographs of VEGFA antibody immunohistochemistry and blood vessels labeled by yellow allows, scale bar = 500 μm (40×) and 50 μm (400×). (E) Quantification of immunohistochemical staining intensity (VEGFA antibody). (F) Quantification of average number of blood vessels. Data were mean ± SD. *P < .05 and **P < .01 vs the control group, #P < .05 and ##P < .01 vs the model group, $P < .05 and $$P < .01 vs the HA group.

Article Snippet: The antibodies against PCNA (NB500-106) and VEGFA (NB100-664) were purchased from Novus Biologicals, Inc., the antibodies against β-actin (A3854), p-p38 (Thr180/Tyr182, 4511), total p38 (87869), total JNK (9252S), p-JNK (Thr183/Tyr185, 9255S), p-ERK1/2 (p-p44/42, Thr202/Tyr204, 4370), total ERK1/2 (p44/42, 4695), p-Akt (Ser473, 4060T), and total Akt (4691T) were purchased from Cell Signaling Technology, Inc., and horseradish peroxidase–conjugated antibody was purchased from Zhongshan Jinqiao Biotechnology Co., Ltd.

Techniques: Staining, Immunohistochemistry, Labeling, Immunohistochemical staining, Control

Journal:

Article Title: Functional and structural remodeling of the myocardial microvasculature in early experimental hypertension

doi: 10.1152/ajpheart.00538.2005

Figure Lengend Snippet: Left, protein expression of VEGF (Western blot and immunohistochemistry) in the transmural myocardium of normal and HT pigs. Right, level (ELISA) and immunohistochemistry of bFGF in the transmural myocardium of normal and hypertensive pigs. Myocardial expression of both bFGF and VEGF was significantly increased in HT animals. Immunohistochemistry showed that bFGF is expressed mainly in vascular smooth muscle cells and myocytes, and VEGF in endothelial cells, and that their increased expression appears to be uniform throughout the myocardium. *p<0.05 compared to normal.

Article Snippet: Mouse monoclonal antibodies anti-VEGF (A-20, dilution 1:100, R&D Systems, Minneapolis, MN) and bFGF-2 (#147, 1:100, R&D Systems, Minneapolis, MN) served as primary antibodies.

Techniques: Expressing, Western Blot, Immunohistochemistry, Enzyme-linked Immunosorbent Assay